Market Research Report
Mergers and Acquisitions in the Global Life Sciences Industry, 2018
|Published by||Frost & Sullivan||Product code||808217|
|Published||Content info||78 Pages
Delivery time: 1-2 business days
|Mergers and Acquisitions in the Global Life Sciences Industry, 2018|
|Published: March 7, 2019||Content info: 78 Pages||
M&As for Growth in Patient Engagement, Artificial Intelligence and Big Data Analytics are Driving Greater Vertical Integration
The Healthcare industry has witnessed some of the largest mega-mergers in 2018 - mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Industry report provide details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, contract services diagnostic, and other life science sectors.
The report provides a detailed understanding and analysis of how and why companies enter M&A deals, which legislative and regulatory policies are promoting M&A activities, and how APAC investors are growing their presence in developed economies, undeterred by policy uncertainties. It also highlights the growing influence of non-traditional players in the life science space and their impact in steering the direction of M&A activity of the traditional players. It further brings out the growing acceptance of digital revenue streams, an under-explored opportunity in connected health. The exponential growth of private equity (PE) investors, and their appetite to invest in high-risk areas, has also allowed unlocking of the potential of several new technologies, creating a ripe environment for corporate acquisitions. At the same time, PE investors' ability to bid for higher value deals has created competition for the same targets, often outbidding corporate investors.
This study dives deeper into each stakeholder segment to uncover their unique M&A dynamics and chart the activity of top 10 companies in each segment. Several biopharma companies have relied on smaller acquisitions to bolster their R&D pipelines, whereas several others have sought high-value deals to merge or acquire competitor companies in order to achieve critical mass in R&D and ensure continued growth and dominance in the global marketplace. Contract service organizations (CSO) are experiencing the highest rate of consolidation, with the goal of emerging as one-stop-shop solution providers. However, CSOs will soon have to think beyond mere capacity expansion and acquire targets specialized in tangential services like supply chain and patient connectedness. Diagnostic and research tool (DRT) OEMs have experienced a different M&A trend and will have to rely more on value-add services to overcome the slump in M&A derived growth. Strategic imperatives for companies to recalibrate their business models and be future ready are provided in this study as well. Finally, the study also briefly covers growing trends in the outsourcing of innovation, production and selling, and the heightened importance of innovation hubs in promoting M&A.